Clinical trial
Oral Rigosertib for Squamous Cell Carcinoma
NCT01807546
Study timeline
Study start (unknown)2013-03-01Date precision: month
Registry last updated2017-06-26
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Head and Neck Squamous Cell Carcinomaunresolved
Anal Squamous Cell Carcinomaunresolved
Lung Squamous Cell Carcinomaunresolved
Cervical Squamous Cell Carcinomaunresolved
Esophageal Squamous Cell Carcinomaunresolved
Skin Squamous Cell Carcinomaunresolved
Penile Squamous Cell Carcinomaunresolved
Interventions
rigosertibDRUG
Sponsors & collaborators
Traws Pharma, Inc.lead sponsor
Mapped research locations
New YorkNew York, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1ColumbusOhio, United States1AuroraColorado, United States1DenverColorado, United States1Ann ArborMichigan, United States1The BronxNew York, United States1SacramentoCalifornia, United States1StanfordCalifornia, United States1FairfaxVirginia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01807546 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.